By Sabela Ojea Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine.
By Colin Kellaher Selecta Biosciences is suspending further investment in most of its pipeline, as the biotechnology company focuses on the advancement of.